DelveInsight Report Details Interleukin-23 (IL-23) Inhibitor Pipeline

Market research firm DelveInsight has published a new report offering insights into the development pipeline of Interleukin-23 (IL-23) inhibitor therapies. The report, titled "Interleukin-23 (IL-23) Inhibitor - Pipeline Insight, 2026," provides a comprehensive overview of ongoing and planned clinical and preclinical studies.

The analysis covers therapies currently under development, detailing their mechanisms of action, stages of development, routes of administration, and molecular types. It also highlights the efforts of various companies and academic institutions in this therapeutic area, identifying key players and their respective projects.

DelveInsight's assessment includes both commercial and clinical evaluations of the pipeline products. Information on collaborations, licensing agreements, mergers and acquisitions, and funding arrangements that impact drug development progress is also provided. The report acknowledges projects that may have been dormant or discontinued.

The firm bases its findings on data from proprietary databases, company and university websites, clinical trial registries, conferences, and regulatory filings. The report aims to support decision-making for pharmaceutical companies and identify opportunities within the IL-23 inhibitor market.